1527 related articles for article (PubMed ID: 31629009)
21. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
[TBL] [Abstract][Full Text] [Related]
22. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
25. [T cell-based immunotherapies in solid tumors].
Baulu E; Dougé A; Chuvin N; Bay JO; Depil S
Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813
[TBL] [Abstract][Full Text] [Related]
26. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
27. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
28. Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.
Pellegrino M; Del Bufalo F; De Angelis B; Quintarelli C; Caruana I; de Billy E
Cells; 2020 Dec; 10(1):. PubMed ID: 33374128
[TBL] [Abstract][Full Text] [Related]
29. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.
Wang L; Zhang L; Dunmall LC; Wang YY; Fan Z; Cheng Z; Wang Y
Cancer Lett; 2024 Jun; 591():216871. PubMed ID: 38604310
[TBL] [Abstract][Full Text] [Related]
30. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.
Talleur AC; Fabrizio VA; Aplenc R; Grupp SA; Mackall C; Majzner R; Nguyen R; Rouce R; Moskop A; McNerney KO
Transplant Cell Ther; 2024 Jun; 30(6):565-579. PubMed ID: 38588880
[TBL] [Abstract][Full Text] [Related]
31. Car T Cells in Solid Tumors: Overcoming Obstacles.
Rojas-Quintero J; Díaz MP; Palmar J; Galan-Freyle NJ; Morillo V; Escalona D; González-Torres HJ; Torres W; Navarro-Quiroz E; Rivera-Porras D; Bermúdez V
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673757
[TBL] [Abstract][Full Text] [Related]
32. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
33. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors.
Li S; Xia Y; Hou R; Wang X; Zhao X; Guan Z; Ma W; Xu Y; Zhang W; Liu D; Zheng J; Shi M
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167159. PubMed ID: 38583815
[TBL] [Abstract][Full Text] [Related]
34. Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.
Fu M; Tang L
Recent Pat Anticancer Drug Discov; 2019; 14(1):60-69. PubMed ID: 30636615
[TBL] [Abstract][Full Text] [Related]
35. [Not Available].
Alcazer V; Delenda C; Poirot L; Depil S
Bull Cancer; 2018 Dec; 105 Suppl 2():S178-S187. PubMed ID: 30686356
[TBL] [Abstract][Full Text] [Related]
36. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.
Bell M; Gottschalk S
Front Immunol; 2021; 12():684642. PubMed ID: 34177932
[TBL] [Abstract][Full Text] [Related]
37. Altered cancer metabolism and implications for next-generation CAR T-cell therapies.
Ramapriyan R; Vykunta VS; Vandecandelaere G; Richardson LGK; Sun J; Curry WT; Choi BD
Pharmacol Ther; 2024 Jul; 259():108667. PubMed ID: 38763321
[TBL] [Abstract][Full Text] [Related]
38. [Mechanisms of resistance and escape to CAR-T cells].
Grinda T; Brouard J; Tran D; Rubio MT
Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
[TBL] [Abstract][Full Text] [Related]
39. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
40. CAR-T in solid tumors: Blazing a new trail through the brambles.
Guo F; Cui J
Life Sci; 2020 Nov; 260():118300. PubMed ID: 32827541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
